Lab Von Herrath

Von Herrath

Pancreatic tissue transplanted in TheraCyteTM encapsulation devices is protected and prevents hyperglycemia in a mouse model of immune-mediated diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Genetic-induced variatons in the GAD65 T cell repetoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Viral triggers for autoimmunity: is the glass of molecular mimicry half full or half empty

Ricardo Monterrosa
June 6, 2024

Von Herrath

Combination therapies for type 1 diabetes: why not now

Ricardo Monterrosa
June 6, 2024

Von Herrath

99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: viruses, autoimmunity and immunogregulation

Ricardo Monterrosa
June 6, 2024

Von Herrath

Miminal effect of CD103 expression on the control of a chronic antiviral immune response

Ricardo Monterrosa
June 6, 2024

Von Herrath

Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection

Ricardo Monterrosa
June 6, 2024

Von Herrath

Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment

Ricardo Monterrosa
June 6, 2024

Von Herrath

Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Giabetes Combination Therapy Assessment Group

Ricardo Monterrosa
June 6, 2024

Von Herrath

Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and INFgamma

Ricardo Monterrosa
June 6, 2024

Von Herrath

Antigen-specific immuotherapy for type 1 diabetes: maximizing the potentia

Ricardo Monterrosa
June 6, 2024

Von Herrath

Dimorphic histopathology of long-standing childhood-onset diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology

Ricardo Monterrosa
June 6, 2024

Von Herrath

Increased memory conversion of naïve CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure

Ricardo Monterrosa
June 6, 2024

Von Herrath

Type 1 diabetes: etiology, immunology, and therapeutic strategies

Ricardo Monterrosa
June 6, 2024

Von Herrath

Immunotherapy of type 1 diabetes – how to rationally priotize combination therapies in T1D

Ricardo Monterrosa
June 6, 2024

Von Herrath

A novel technique for the in vivo imaging of autoimmune diabetes development in the pancras by two-photon microscopy

Ricardo Monterrosa
June 6, 2024

Croft, Von Herrath

Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection

Ricardo Monterrosa
June 6, 2024

Von Herrath

Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesis

Ricardo Monterrosa
June 6, 2024

Von Herrath

Type 1 diabetes vaccine development: animal models vs. humans

Ricardo Monterrosa
June 6, 2024

Von Herrath

Protection against or triggering of Type 1 diabetes? Different roles for viral infections

Ricardo Monterrosa
June 6, 2024

Von Herrath

Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model

Ricardo Monterrosa
June 6, 2024

Von Herrath

Humanizing animal models: a key to autoimmune diabetes treatement

Ricardo Monterrosa
June 6, 2024

Von Herrath

TLR2 signaling improves immunoregulation to prevent type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay

Ricardo Monterrosa
June 6, 2024

Croft, Von Herrath

Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis

Ricardo Monterrosa
June 6, 2024

Von Herrath

How does type 1 diabetes develop?: The notion of homicide or β-cell suicide revisited

Ricardo Monterrosa
June 6, 2024

Von Herrath

Do viral infections protect from or enhance type 1 diabetes and how can we tell the difference?

Ricardo Monterrosa
June 6, 2024

Von Herrath

Immunosuppressive mechanisms during viral infectious diseases

Ricardo Monterrosa
June 6, 2024

Von Herrath

Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virall induced model

Ricardo Monterrosa
June 6, 2024

Von Herrath

How viral infections enhance or prevent type 1 diabetes-from mouse to man

Ricardo Monterrosa
June 6, 2024

Von Herrath

Incidental CD8 T cell reactivity against caspase-cleaved apoptotic self-antigens from ubiquitously expressed proteins in islets from pediabetic human leucocyte antigen-A2 transgenic non-obese diabetic mice

Ricardo Monterrosa
June 6, 2024

Von Herrath

2011 Update: antigen-specific therapy in type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Persistent glucose transporter expression on pancreatic beta cells from longstanding type 1 diabetes individuals

Ricardo Monterrosa
June 6, 2024

Von Herrath

Viruses and cytotoxic T lymphocytes in type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Croft, Von Herrath

Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment

Ricardo Monterrosa
June 6, 2024

Von Herrath

Immunology in the clinic review series: focus on type 1 diabetes and viruses: the role of viruses in type 1 diabetes: a difficult dilemma

Ricardo Monterrosa
June 6, 2024

Von Herrath

Can an immune-regulatory vaccine prevent HIV infection?

Ricardo Monterrosa
June 6, 2024

Von Herrath

Combination therapy with InsB9-23 peptide immunization and CTLA4-IgG does not reverse diabetes in NOD mice

Ricardo Monterrosa
June 6, 2024

Von Herrath

Motifs for a deadly encounter

Ricardo Monterrosa
June 6, 2024

Von Herrath

Unraveling the autoimmune translational research process layer by layer

Ricardo Monterrosa
June 6, 2024

Von Herrath

Intravital imaging of CTLS killing islet cells in diabetic mice

Ricardo Monterrosa
June 6, 2024

Von Herrath

Virus infectons in type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Demonstration of islet-autoreactive CD8 T cells I insulitic lesions from recent onset and long-term type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Cheroutre, Croft, Von Herrath

Following the fate of one insulin-reactive CD4 T cell: conversion into teffs and tregs in the periphery controls deiabetes in NOD mice

Ricardo Monterrosa
June 6, 2024

Von Herrath

IL-7 receptor α blockade, an off-switch for autoreactive T cells

Ricardo Monterrosa
June 6, 2024

Von Herrath

The microbiology of human hygiene and its impact on type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Infection as a cause of type 1 diabetes?

Ricardo Monterrosa
June 6, 2024

Von Herrath

TGF-β blockade does not improve control of an established persistent viral infection

Ricardo Monterrosa
June 6, 2024

Von Herrath

Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabets in combination with anti-CD3

Ricardo Monterrosa
June 6, 2024

Von Herrath

Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets

Ricardo Monterrosa
June 6, 2024

Von Herrath

Introduction to preventative and predictive medicine: past experience and future reality

Ricardo Monterrosa
June 6, 2024

Croft, Crotty, Von Herrath

OX40 facilitates control of a persistent virus infection

Ricardo Monterrosa
June 6, 2024

Von Herrath

Blockade but not overexpression of the junctional adhesion molecule C influences virus-induced type 1 diabetes in mice

Ricardo Monterrosa
June 6, 2024

Von Herrath

Viral infections and molecular mimicry in type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Antibody cross-reactivity and the viral aetiology of type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Progress in immune-based therapies for type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation

Ricardo Monterrosa
June 6, 2024

Von Herrath

Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice

Ricardo Monterrosa
June 6, 2024

Von Herrath

Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model

Ricardo Monterrosa
June 6, 2024

Von Herrath

Combination therapy with anti-CD6 and oral insulin immunisation reverses recent onset diabetes in non obese diabetic mice but fails to induce lasting tolerance

Ricardo Monterrosa
June 6, 2024

Croft, Crotty, Von Herrath

Exogenous OX40 stimulation during lymphocytic choriomeningitis virus infection impairs follicular Th cell differentiation and diverts DC4 T cells into the effector lineage by upregulating blimp-1

Ricardo Monterrosa
June 6, 2024

Von Herrath

The diagnosis of insulitis in human type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Peters, Von Herrath

Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessment

Ricardo Monterrosa
June 6, 2024

Von Herrath

Trials in type 1 diabetes: antigen-specific therapies

Ricardo Monterrosa
June 6, 2024

Von Herrath

Keeping the patient perspective: where are we in the world of type 1 diapetes?

Ricardo Monterrosa
June 6, 2024

Von Herrath

Metabolic syndrome – removing roadbloacks to therapy: antigenic immunotherapies

Ricardo Monterrosa
June 6, 2024

Von Herrath

Direct infection of dendritic cells during chronic viral infection suppresses antiviral T cell proliferation and induces IL-10 expression in CD4 T cells

Ricardo Monterrosa
June 6, 2024

Von Herrath

CTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients

Ricardo Monterrosa
June 6, 2024

Von Herrath

Combination therapy with an anti-IL-1β and GAD65 DNA vaccine can reverse recent-onset diabetes in RIP-GP mouse model

Ricardo Monterrosa
June 6, 2024

Peters, Von Herrath

CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Potential viral pathogenic mechanism in human type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Regulatory T cells control diabetes without compromising acute anti-viral defence

Ricardo Monterrosa
June 6, 2024

Von Herrath

The type 1 diabetes signature: hardwired to trigger inflammation?

Ricardo Monterrosa
June 6, 2024

Von Herrath

Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

BDC12-4.1 T-cell receptor transgenic insulin-specific CD4 T cells are resistant to in vitro differentiation into functional Foxp3+ T regulatory cells

Ricardo Monterrosa
June 6, 2024

Von Herrath

Higher proinflammatory cytokine production and spontaneous activation in some type 1 and type 2 diabetic subjects

Ricardo Monterrosa
June 6, 2024

Von Herrath

Inflammation and hyperglycemia mediate Deaf1 splicing in pancreatic lymph nodes via distinct pathways during type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Enteroviruses, hygiene and type 1 diabetes: toward a preventive vaccine

Ricardo Monterrosa
June 6, 2024

Von Herrath

Beta-cell specific production of IL6 in conjunction with a mainly intracellular but not mainly surface viral protein causes diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Enterovirus infection and type 1 diabetes: closing in on a link?

Ricardo Monterrosa
June 6, 2024

Von Herrath

The Hsp60 peptide p77 enhances anti-CD3 mediated diabetes remission in non-obest diabetic mice

Ricardo Monterrosa
June 6, 2024

Von Herrath

Current concepts on the pathogenesis of type 1 diabetes-considerations for attempts to prevent and reverse the disease

Ricardo Monterrosa
June 6, 2024

Von Herrath

Heterogenity and loblarity of pancreatic pathology in type 1 diabetes during the prediabetic phase

Ricardo Monterrosa
June 6, 2024

Von Herrath

CD4 T cell differentiation in type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Recent advances in understanding type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Factors impeding the discovery of an intervention-based treatment for type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

Oral insulin (human, murine, or porcine) does not prevent diabetes in the non-obese diabetic mouse

Ricardo Monterrosa
June 6, 2024

Von Herrath

A preclinical consortium approach for assessing the efficacy of combined anti-CD3 plus IL-1 blockade in reversing new-onset autoimmune diabetes in NOD mice

Ricardo Monterrosa
June 6, 2024

Von Herrath

A deeper look into type 1 diabetes – imaging immune responses during onset of disease

Ricardo Monterrosa
June 6, 2024

Von Herrath

CD40L expression by CD4+ but not CD8+ T cells regulates antiviral immune responses in acute LCMV infection in mice

Ricardo Monterrosa
June 6, 2024

Von Herrath

Immunotherapy for type 1 diabetes: why do current protocols not halt the underlying disease process?

Ricardo Monterrosa
June 6, 2024

Von Herrath

Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes

Ricardo Monterrosa
June 6, 2024

Von Herrath

The viral paradigm in type 1 diabetes: who are the main suspects?

Ricardo Monterrosa
June 6, 2024

Von Herrath

Increase in pancreatic proinsulin and preservation of β-cell mass in autoantibody positive donors prior to type 1 diabetes onset

Ricardo Monterrosa
June 6, 2024

Von Herrath

Re-addressing the 2013 consensus guidelines for the diagnosis of insulitis in human type 1 diabetes: is change necessary?

Ricardo Monterrosa
June 6, 2024

Von Herrath

Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes

Ricardo Monterrosa
June 6, 2024

contact@lji.org
9420 Athena Circle
La Jolla, CA 92037

Phone: +1 (858) 752-6500

© 2024 La Jolla Institute for Immunology. All rights reserved. LJI is a 501(c)(3) tax-exempt organization. Federal Tax ID Number 33-0328688